News
We’ve made a London Life Sciences Week Guide
Heading to London this November? Explore Onyx’s independent guide to the events and make the most of 15–19 November 2026.
Follow Onyx
LinkedIn Read us in Fortune SubscribeCell & Gene Meeting on the Mesa 2026
-
Granza Bio pairs T-cell ‘attack particles’ with CAR-T in a single targeted particle, CEO says at Meeting on the Mesa
-
Orca Bio CEO says Tregzi launch hinges on getting manufacturing right every time, at Meeting on the Mesa
-
Ori Biotech weighs moving some manufacturing to China, CEO tells Meeting on the Mesa panel
-
Tenaya Therapeutics to update on pivotal plans for heart gene therapies by year end, CEO says at Meeting on the Mesa
Coming up
Cell & Gene Leaders Live
One-day summit for cell & gene therapy leaders, timed with London Life Sciences Week (15–20 November 2026) and the Jefferies London Healthcare Conference.
Get tickets →
See the programme →
London Life Sciences Week Guide
The unofficial London Life Sciences Week Guide, published by Onyx Newsroom. Every event 15–19 November 2026 — filter by day and audience, build an itinerary.
Plan your week →
Granza Bio pairs T-cell ‘attack particles’ with CAR-T in a single targeted particle, CEO says at Meeting on the Mesa
Granza Bio is co-delivering CAR mRNA and mRNA for supramolecular attack particles (SMAPs) to T cells in one targeted particle, CEO Ashwin Nandakumar said, citing preclinical data on improved killing and an apoptotic mode of cell death.
Published 18 Oct 2026
Orca Bio CEO says Tregzi launch hinges on getting manufacturing right every time, at Meeting on the Mesa
Orca Bio CEO Nate Fernhoff, Pierre Fabre Pharmaceuticals CEO Adriana Herrera and Ocugen CEO Shankar Musunuri discussed launches, resubmissions and reimbursement on a leadership panel at Cell & Gene Meeting on the Mesa.
Published 18 Oct 2026
Ori Biotech weighs moving some manufacturing to China, CEO tells Meeting on the Mesa panel
Ori Biotech CEO Jason Foster said the company is considering moving some manufacturing to China to compete on price there, as a panel with Arbor Biotechnologies and CoJourney debated China's new clinical research rules, speed and costs.
Published 18 Oct 2026
Tenaya Therapeutics to update on pivotal plans for heart gene therapies by year end, CEO says at Meeting on the Mesa
Tenaya CEO Faraz Ali said the company will update on pivotal trial talks for TN-201 in HCM and TN-401 in ARVC by the end of 2026, citing interim data that Ali said showed reduced hypertrophy and arrhythmia burden.
Published 18 Oct 2026
Kyverna on track to complete miv-cel filing in stiff person syndrome this quarter, CEO says at Meeting on the Mesa
Warner Biddle told Cell & Gene Meeting on the Mesa that Kyverna expects to complete its rolling BLA for miv-cel in stiff person syndrome in Q4 2026, and set out one-year data in SPS and myasthenia gravis and plans in progressive MS.
Published 18 Oct 2026
Roche licenses Rona's ALK7 RNAi obesity candidate in deal worth up to $1.16 billion
Rona Therapeutics said Roche took an exclusive worldwide license to its ALK7-targeting RNAi candidate for obesity, with up to $100 million in upfront and near-term payments.
Published 15 Oct 2026
Onyx Live.
From the conference floor ↗
Kim Brown, CEO, Compass Biomedical | Onyx Live | ISCT Dublin 2026
Jason Jones, Head of Global Business Development, Cellular Origins | Onyx Live | ISCT Dublin 2026
Dimitrios Kouroupis, Professor, University of Miami | Onyx Live | ISCT Dublin 2026
Jon Ellis, CEO, Trenchant BioSystems | Onyx Live | ISCT Dublin 2026
Sean Werner, CTO, BioLife Solutions | Onyx Live | ISCT Dublin 2026
News.
All news ↗Roche licenses Rona's ALK7 RNAi obesity candidate in deal worth up to $1.16 billion
Rona Therapeutics said Roche took an exclusive worldwide license to its ALK7-targeting RNAi candidate for obesity, with up to $100 million in upfront and near-term payments.
Novartis to acquire Excellergy, adding Phase 1 anti-IgE program
Deal brings Exl-111 into Novartis’s allergy portfolio, targeting IgE-driven diseases including food allergy and asthma.
Kali licenses KT501 to Sanofi in autoimmune disease deal
Sanofi will obtain exclusive worldwide rights to Kali Therapeutics’ KT501 under an agreement covering a tri-specific T-cell engager for B cell-mediated autoimmune diseases.
India semaglutide market sees new moves from Lupin, Zydus, and Sun Pharma
Lupin gained semi-exclusive rights to co-market Zydus’ semaglutide injection in India, while Sun Pharma launched Noveltreat and Sematrinity for chronic weight management and type 2 diabetes.
FDA expands IMCIVREE label to acquired hypothalamic obesity as EMANATE misses primary endpoints
Rhythm Pharmaceuticals said the FDA approved IMCIVREE for acquired hypothalamic obesity, making it the first FDA-approved therapy for the condition.
Abbott completes Exact Sciences deal, expanding diagnostics portfolio in cancer screening
The deal increases Abbott’s exposure to a U.S. cancer screening and precision oncology diagnostics market the company sizes at $60 billion.
Aldeyra receives FDA complete response letter for Reproxalap
The FDA issued a Complete Response Letter for Aldeyra’s reproxalap application in dry eye disease, citing insufficient evidence of efficacy and inconsistent trial results.
Novartis expands Cosentyx label with FDA approval in adolescent Hidradenitis Suppurativa
The FDA approval extends Cosentyx into pediatric hidradenitis suppurativa, with use supported by adult studies, pharmacokinetic modeling, and pediatric data from other approved indications
China approves commercial BCI system for cervical spinal cord injury patients
The approved NEO system is designed to restore hand-grasping ability through neural signal decoding and a robotic glove.
Lilly escalates compounding challenge after finding impurity in Tirzepatide-B12 products
Eli Lilly said testing found an impurity in compounded tirzepatide products mixed with vitamin B12 and urged FDA action.
Bristol Myers Squibb’s Mezigdomide Delivers Progression-Free Survival Benefit in Phase 3 SUCCESSOR-2 Trial
SUCCESSOR-2 is mezigdomide’s first positive Phase 3 study and the CELMoD program’s second. The trial showed a progression-free survival benefit over carfilzomib and dexamethasone alone.
BioNTech sets leadership transition as Sahin and Türeci plan move to new mRNA company
BioNTech said its pipeline and COVID-19 vaccine franchise remain unaffected as its co-founders prepare to move to a new independent mRNA company.
Exclusive interviews.
All interviews ↗Inside the next breakthrough.
ME Therapeutics' Salim Dhanji on making the patient's body the bioreactor
The Vancouver immunologist on myeloid cells as a delivery route, STING for cold tumours, and why in vivo CAR could land near the price of a checkpoint inhibitor.
Creasallis' Zahra Jawad on why US investors said yes before Cambridge did
The Cambridge founder on re-engineering antibodies to break into solid tumours, raising a seed round without a professor behind her, and why hiring in the UK is her hardest problem.
The primal blueprint: how CamMed mimics evolution to reinvent self-amplifying RNA
CamMed CEO Dr. Ahmet Can Berkyurek on an AI-discovered, single-protein replicase drawn from biology's most ancient machinery — and his case for building it in the UK
Clene Nanomedicine's ALS drug is a gold nanocrystal you drink. It missed its primary endpoint. The FDA is still listening.
CEO Rob Etherington and chief scientist Mark Mortenson on the bioenergetic thesis behind CNM-Au8, the HEALEY data, and five meetings with the agency.
FDA Greenlit.
Approvals, explained ↗FDA Season 2026 — Scorecard
Pierre Fabre / Atara
Tabelecleucel (Ebvallo)
EBV+ Post-Transplant Lymphoproliferative Disease
Aquestive Therapeutics
Anaphylm (dibutepinephrine)
Anaphylaxis
REGENXBIO
RGX-121 (clemidsogene)
Hunter Syndrome (MPS II)
Aldeyra Therapeutics
Reproxalap
Dry Eye Disease
Vanda Pharmaceuticals
Tradipitant
Gastroparesis
FDA approves GSK's Jideytro for ROS1-positive lung cancer, a week after the Nuvalent acquisition closed
FDA approves Merck's Lipfendra, a once-daily oral PCSK9 inhibitor for lowering LDL cholesterol
FDA approves Celcuity's Revtorpyk for PIK3CA wild-type breast cancer after CDK4/6 failure
FDA grants Vera's Trutakna accelerated approval to reduce proteinuria in IgA nephropathy
FDA approvals - June 2026
FDA approves Viridian's Lumvoa for thyroid eye disease in both active and chronic disease
Press releases.
Company announcements ↗
TLDRBiotech(too long, didn't read)
Anis Fahandej-SadiHead Editor, TLDR Biotech
The top stories in biotech & pharma, straight to your inbox in only one email.The good, the bad and the ugly.
SubscribeOnyx, in your corner
Keep your finger
on what’s next.
Follow the people, science and decisions shaping biotech. Explore Onyx membership.
Subscribe to Onyx
Already a member? Sign in
